S&P 500   5,044.20 (+0.44%)
DOW   38,010.74 (+0.68%)
QQQ   426.17 (+0.08%)
AAPL   168.13 (+0.08%)
MSFT   408.42 (-0.83%)
META   507.55 (+2.71%)
GOOGL   156.04 (+0.37%)
AMZN   181.17 (-0.06%)
TSLA   151.16 (-2.76%)
NVDA   846.91 (+0.78%)
AMD   154.87 (+0.55%)
NIO   4.02 (+2.81%)
BABA   69.34 (+0.76%)
T   16.16 (+0.25%)
F   12.11 (+0.58%)
MU   117.10 (+0.66%)
GE   157.73 (+1.32%)
CGC   6.95 (+7.09%)
DIS   113.49 (+0.49%)
AMC   2.81 (-5.70%)
PFE   25.40 (-0.08%)
PYPL   63.11 (-0.24%)
XOM   118.84 (+0.18%)
S&P 500   5,044.20 (+0.44%)
DOW   38,010.74 (+0.68%)
QQQ   426.17 (+0.08%)
AAPL   168.13 (+0.08%)
MSFT   408.42 (-0.83%)
META   507.55 (+2.71%)
GOOGL   156.04 (+0.37%)
AMZN   181.17 (-0.06%)
TSLA   151.16 (-2.76%)
NVDA   846.91 (+0.78%)
AMD   154.87 (+0.55%)
NIO   4.02 (+2.81%)
BABA   69.34 (+0.76%)
T   16.16 (+0.25%)
F   12.11 (+0.58%)
MU   117.10 (+0.66%)
GE   157.73 (+1.32%)
CGC   6.95 (+7.09%)
DIS   113.49 (+0.49%)
AMC   2.81 (-5.70%)
PFE   25.40 (-0.08%)
PYPL   63.11 (-0.24%)
XOM   118.84 (+0.18%)
S&P 500   5,044.20 (+0.44%)
DOW   38,010.74 (+0.68%)
QQQ   426.17 (+0.08%)
AAPL   168.13 (+0.08%)
MSFT   408.42 (-0.83%)
META   507.55 (+2.71%)
GOOGL   156.04 (+0.37%)
AMZN   181.17 (-0.06%)
TSLA   151.16 (-2.76%)
NVDA   846.91 (+0.78%)
AMD   154.87 (+0.55%)
NIO   4.02 (+2.81%)
BABA   69.34 (+0.76%)
T   16.16 (+0.25%)
F   12.11 (+0.58%)
MU   117.10 (+0.66%)
GE   157.73 (+1.32%)
CGC   6.95 (+7.09%)
DIS   113.49 (+0.49%)
AMC   2.81 (-5.70%)
PFE   25.40 (-0.08%)
PYPL   63.11 (-0.24%)
XOM   118.84 (+0.18%)
S&P 500   5,044.20 (+0.44%)
DOW   38,010.74 (+0.68%)
QQQ   426.17 (+0.08%)
AAPL   168.13 (+0.08%)
MSFT   408.42 (-0.83%)
META   507.55 (+2.71%)
GOOGL   156.04 (+0.37%)
AMZN   181.17 (-0.06%)
TSLA   151.16 (-2.76%)
NVDA   846.91 (+0.78%)
AMD   154.87 (+0.55%)
NIO   4.02 (+2.81%)
BABA   69.34 (+0.76%)
T   16.16 (+0.25%)
F   12.11 (+0.58%)
MU   117.10 (+0.66%)
GE   157.73 (+1.32%)
CGC   6.95 (+7.09%)
DIS   113.49 (+0.49%)
AMC   2.81 (-5.70%)
PFE   25.40 (-0.08%)
PYPL   63.11 (-0.24%)
XOM   118.84 (+0.18%)
Free Trial
NASDAQ:APGN

Apexigen (APGN) Stock Price, News & Analysis

→ A new way to collect income from stocks (From DTI) (Ad)
Free APGN Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$0.39
▼
$0.39
50-Day Range
$0.36
▼
$0.44
52-Week Range
$0.33
▼
$8.28
Volume
N/A
Average Volume
967,731 shs
Market Capitalization
$9.57 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock Analysis
Stock Analysis
APGN stock logo

About Apexigen Stock (NASDAQ:APGN)

Apexigen, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody therapeutics for oncology. It develops a pipeline of product candidates, including APX005M, a humanized agonist antibody that is in Phase II clinical development for the treatment of solid tumors, such as melanoma, esophageal and gastroesophageal junction, sarcoma, and ovarian cancers in combination with immunotherapy, chemotherapy, radiation therapy, and cancer vaccines; and APX601, a humanized antagonist antibody that is in Phase I/II clinical trial for the treatment of multiple tumor indications, as well as APX801, an NK cell engager to activate natural killer cells to killing of tumor cells. Apexigen, Inc. was founded in 2010 and is headquartered in San Carlos, California.

APGN Stock News Headlines

September 7, 2023 | seekingalpha.com
Pyxis Oncology: Catalysts Ahead, Cash In Hand And An Acquisition Completed
August 11, 2023 | markets.businessinsider.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AVID, CPRI, APGN
April 18, 2024 | Crypto Swap Profits (Ad)
Did You Get Your Free Bitcoin Yet?
And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.
June 3, 2023 | finance.yahoo.com
Apexigen Announces Phase 2 Data Evaluating Sotigalimab, its CD40 Agonist Antibody, in Combination with Doxorubicin in Patients with Advanced Soft Tissue Sarcoma Presented at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting
May 27, 2023 | msn.com
EF Hutton Reiterates Apexigen (APGN) Hold Recommendation
May 24, 2023 | markets.businessinsider.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GNL, RTL, APGN
May 17, 2023 | msn.com
EF Hutton Maintains Apexigen (APGN) Buy Recommendation
May 16, 2023 | wsj.com
APG SGA S.A.
April 18, 2024 | Crypto Swap Profits (Ad)
Did You Get Your Free Bitcoin Yet?
And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.
March 3, 2023 | finance.yahoo.com
Are Medical Stocks Lagging Apexigen, Inc. (APGN) This Year?
March 3, 2023 | finance.yahoo.com
Are Medical Stocks Lagging Apexigen, Inc. (APGN) This Year?
February 27, 2023 | finance.yahoo.com
Apexigen Announces Review of Strategic Alternatives and Restructuring
January 24, 2023 | finance.yahoo.com
Apexigen Announces Approximately $2.8 Million Private Placement Financing
January 23, 2023 | msn.com
Why Pliant Therapeutics Shares Are Trading Higher By Around 49%; Here Are 20 Stocks Moving Premarket
January 19, 2023 | finance.yahoo.com
Apexigen Touts New Positive Sotigalimab Data Showing Expanded Anti-Tumor Responses
January 19, 2023 | benzinga.com
Thinking about buying stock in Zymeworks, CureVac, Apexigen, Gamida Cell, or Xos?
January 19, 2023 | finance.yahoo.com
Apexigen Announces New Phase 2 Data Evaluating Sotigalimab, its CD40 Agonist Antibody, at ASCO Gastrointestinal Cancers Symposium 2023
January 11, 2023 | benzinga.com
Apexigen Shares Halted On Circuit Breaker To The Upside, Stock Now Up 140.5%
November 15, 2022 | finance.yahoo.com
Apexigen Reports Third Quarter 2022 Financial Results and Provides Business Update
November 11, 2022 | finance.yahoo.com
Apexigen Announces New Data from a Phase 1/2 Trial Evaluating its CD40 Antibody, Sotigalimab, in Combination with Pembrolizumab in Patients with First-Line Metastatic Melanoma at the SITC 2022 Annual Meeting
November 4, 2022 | bizjournals.com
How biotech companies are building drug pipelines with PIPEs
October 19, 2022 | msn.com
Wall Street Set to Open Lower as Higher-Than-Expected UK Inflation Rattles Investors
October 6, 2022 | ca.finance.yahoo.com
Apexigen, Inc. (APGN)
September 12, 2022 | finance.yahoo.com
Apexigen's Shares Fall After Data From Gastric Cancer Candidate
September 10, 2022 | finance.yahoo.com
Apexigen Presents New Data from a Phase 2 Trial Evaluating its CD40 Antibody, Sotigalimab, in Combination with Neoadjuvant Chemoradiation in Patients with Resectable Esophageal and Gastroesophageal Junction Cancers at ESMO Congress 2022
September 7, 2022 | finance.yahoo.com
Apexigen to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
September 5, 2022 | finance.yahoo.com
Apexigen Announces New Data from a Phase 2 Trial Evaluating its CD40 Antibody, Sotigalimab, in Combination with Neoadjuvant Chemoradiation in Patients with Resectable Esophageal and Gastroesophageal Junction Cancers at ESMO Congress 2022
See More Headlines
Receive APGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Apexigen and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
4/18/2024
Fiscal Year End
12/31/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:APGN
CUSIP
N/A
CIK
1814140
Web
www.apexigen.com
Phone
650-931-6236
Fax
N/A
Employees
11
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-32,070,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-614.82%
Return on Assets
-133.30%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.82
Quick Ratio
0.82

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.09) per share
Price / Book
-4.28

Miscellaneous

Outstanding Shares
24,862,000
Free Float
20,088,000
Market Cap
$9.57 million
Optionable
Not Optionable
Beta
3.60
Beginner's Guide to Pot Stock Investing Cover
Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Dr. Xiaodong Yang M.D. (Age 62)
    Ph.D., CEO & Director
    Comp: $532.99k
  • Mr. Francis W. Sarena (Age 52)
    Pres & COO
    Comp: $474.19k
  • Dr. Frank J. Hsu M.D. (Age 62)
    Chief Medical Officer
    Comp: $520.92k
  • Mr. William E. Duke Jr. (Age 51)
    Chief Financial Officer
  • Ms. Amy Wong (Age 57)
    Sr. VP of Fin. & Operations
  • Dr. Jason Wright Ph.D.
    Sr. VP of CMC

Key Competitors

View All Competitors

This page (NASDAQ:APGN) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners
Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!
Priority Gold
[Urgent!] Generational Wealth Gameplan
Crypto 101 Media
IRS Loophole Gives Americans An Escape From Inflation
Birch Gold
He Is Giving Away Bitcoin
Crypto Swap Profits
The “Perfect Storm” for Gold
Gold Safe Exchange
The "Smart Money" Is Ready for May 1st Are You?
Stansberry Research
Rich Dad Poor Dad Author Shocks Millions With 2024 Crash Warning
American Hartford Gold Group
Top 5 AI Stocks to Buy for 2024
Market Moving Trends